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Abstract This prospective, multicenter, single-arm, open-label Phase III study aimed to
evaluate the efficacy and safety of Privigen® (10% liquid human intravenous immunoglob-
ulin [IVIG], stabilized with L-proline) in patients with chronic inflammatory demyelinating
polyneuropathy (CIDP). Patients received one induction dose of Privigen (2 g/kg body weight
[bw]) and up to seven maintenance doses (1 g/kg bw) at 3-week intervals. The primary effi-
cacy endpoint was the responder rate at completion, defined as improvement of ≥1 point on
the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale. The
preset success criterion was the responder rate being ≥35%. Of the 31 screened patients,
28 patients were enrolled including 13 (46.4%) IVIG-pretreated patients. The overall
responder rate at completion was 60.7% (95% confidence interval [CI]: 42.41%–76.43%).
IVIG-pretreated patients demonstrated a higher responder rate than IVIG-naı¨ve patients
(76.9% vs. 46.7%). The median (25%–75% quantile) INCAT score improved from 3.5
(3.0–4.5) points at baseline to 2.5 (1.0–3.0) points at completion, as did the mean (standard
deviation [SD]) maximum grip strength (66.7 [37.24] kPa vs. 80.9 [31.06] kPa) and the
median Medical Research Council sum score (67.0 [61.5–72.0] points vs. 75.5 [71.5–79.5]
points). Of 108 adverse events (AEs; 0.417 AEs per infusion), 95 AEs (88.0%) were mild
or moderate in intensity and resolved by the end of study. Two serious AEs of hemolysis
were reported that resolved after discontinuation of treatment. Thus, Privigen provided
efficacious and well-tolerated induction and maintenance treatment in patients with CIDP.
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Introduction
The PRIMA (Privigen® Impact on Mobility and
Autonomy) study was designed to investigate the
efficacy and safety of Privigen in the treatment of
patients with chronic inflammatory demyelinating
polyneuropathy (CIDP).
CIDP is an acquired presumed autoimmune
disorder of the peripheral nervous system (Koller
et al., 2005) with a prevalence of 3–9 individuals
per 100,000 adults, according to different studies
(Laughlin et al., 2009). CIDP is characterized by
predominantly symmetrical muscle weakness, often
accompanied by impaired sensation and absent or
diminished tendon reflexes, leading to reduction in
daily activities and quality of life expectations (Koller
et al., 2005; Merkies et al., 2010a). The clinical
course is chronic progressive or relapsing, the latter
more common in young adults (Koller et al., 2005).
Electrodiagnostic tests are mandatory for diagnosis;
major features suggesting a diagnosis of CIDP are
listed in the European Federation of Neurological Soci-
eties/Peripheral Nerve Society (EFNS/PNS) Guideline
(Joint Task Force of the EFNS and the PNS, 2010).
CIDP is commonly treated with corticosteroids
or intravenous immunoglobulin (IVIG) (Hughes et al.,
2008; Joint Task Force of the EFNS and the PNS,
2010). A recent study has compared the efficacy
of both in the induction treatment of CIDP (Nobile-
Orazio et al., 2012). After several randomized trials
showing only a short-term improvement (Vermeulen
et al., 1993; Hahn et al., 1996; Thompson et al., 1996;
Mendell et al., 2001), a randomized, placebo-controlled
study in a large cohort of patients treated with IVIG
was recently conducted, referred to as the ICE study
(10% caprylate-chromatography purified IVIG [IVIG-C]
in CIDP efficacy). The ICE study has demonstrated
both short- and long-term improvements in disability,
as assessed by the adjusted Inflammatory Neuropathy
Cause and Treatment (INCAT) disability scale (Hughes
et al., 2008). These results were supported
by statistically significant and clinically relevant
improvements in objective clinical measures of
maximum grip strength, Medical Research Council
(MRC) sum score, and the INCAT sensory sum score
(Hughes et al., 2008; Merkies et al., 2010b).
Privigen is an L-proline-stabilized 10% liquid human
IVIG that has demonstrated safety and efficacy as a
replacement therapy in primary immunodeficiencies
(Stein et al., 2009) and for immunomodulation in
immune thrombocytopenic purpura (Robak et al.,
2009), and is licensed for those indications in the
EU (2008) and the US (2007).
The PRIMA study aimed to confirm the findings
of the IVIG-C treatment arm of the ICE study (Hughes
et al., 2008) in an open-label study in both previously
treated with IVIG and IVIG treatment-naı¨ve patients.
Materials and Methods
Patients, inclusion and exclusion criteria
Males and females aged 18 years or older with
definite or probable CIDP, as defined by the EFNS/PNS
guidelines (Joint Task Force of the EFNS and the PNS,
2010), previously treated or not treated with IVIG,
were eligible for this study. Patients were considered
not pre-exposed to IVIG (IVIG-naı¨ve) if they had a
newly diagnosed CIDP that had developed over at
least 2 months, or if their treatment was interrupted
for at least 1 year, with a progressive disease that had
deteriorated in the last 2 months prior to enrollment.
Patients treated during the last 6 months with a stable
IVIG dose (maximum dose variation of 20%) at a
constant cycle length of 2–6 weeks (maximum cycle
length variation of 5 days) were eligible for screening.
IVIG-pretreated patients were enrolled in the study
if their adjusted INCAT score deteriorated by ≥1
point during the washout period of up to 10 weeks
(‘adjusted’ was defined as excluding changes from 0
to 1, or vice versa, solely due to upper limb score).
Patients were excluded if they had been diagnosed
with multifocal motor neuropathy with conduction
block, monoclonal gammopathy of undetermined
significance associated with anti-MAG IgM antibodies,
distal acquired demyelinating symmetric neuropa-
thy, or any disease that may have caused similar
symptoms or may have interfered with the treatment
or with the outcome assessments of the study.
Other exclusion criteria were abnormal laboratory
parameters (creatinine >1.5 times the upper limit of
normal [ULN], lactate dehydrogenase >1.5 times ULN,
C-reactive protein >60 mg/dl, hemoglobin <10 g/dl),
plasma exchange 3 months prior to enrollment,
treatment with immunomodulatory agents other
than corticosteroids, methotrexate, or azathioprine
within 6 months before enrollment, or with rituximab
12 months before enrollment.
This study was conducted in accordance with
the International Conference on Harmonization Good
Clinical Practice (ICH GCP) guidelines, and the
Declaration of Helsinki (version of 1996). The study
protocol and all other study-related documents were
reviewed and approved by the local Independent Ethics
Committees. Written informed consent was obtained
from all patients before the start of the study.
Study design
This prospective, multicenter, open-label, single-
arm Phase III study was designed to investigate the
efficacy and safety of Privigen in CIDP.
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The regular IVIG treatment of IVIG-pretreated
patients was interrupted temporally for up to 10 weeks
until disease deterioration occurred (≥1 adjusted
INCAT points) that allowed eligibility. All eligible
patients received a Privigen induction dose (2 g/kg bw)
over 2–5 days, followed by up to seven infusions of
1 g/kg bw at 3-week intervals. Dose reductions were
allowed, if medically indicated. Allowed infusion rates
ranged from 0.5 mg/kg/min to 8.0 mg/kg/min.
Allowed concomitant therapy included cortico-
steroids, methotrexate, or azathioprine for CIDP
treatment if dosage and frequency of these treatments
were stable during the 3 months prior to enrollment
and during the study.
Assessment tools
The outcome measures for this study were
selected based on recommendations from previous
workshops on outcome assessments in inflammatory
neuropathies (Merkies and Lauria, 2006; Lunn et al.,
2008).
The INCAT disability scale was chosen as the
primary outcome, as this scale had demonstrated good
responsiveness in CIDP (Hughes et al., 2001, 2008).
The INCAT disability scale comprises a practical and
functional description of the performance efficiency
of the arms and legs in a checklist form suitable
for semi-standardized interviewing of patients. Daily
arm activities such as dressing the upper part of the
body, doing and undoing buttons and zippers, washing
or brushing hair, and handling coins are scored as
being ‘not affected’, ‘affected but not prevented’,
or ‘prevented’. The leg scale measures problems
regarding walking, taking into account the use of aids.
The INCAT score ranges from 0 (no signs of disability)
to 10 (most severe disability).
An adapted version of the MRC sum score was
calculated by summing up the MRC grades (integers
ranging 0–5) of the following eight muscle pairs on
each side: upper arm abductors, elbow flexors, wrist
extensors, first dorsal interosseos, hip flexors, knee
extensors, foot dorsal flexors, and extensor hallucis
longus. The score ranges from 0 (total paralysis) to 80
(normal strength) (Kleyweg et al., 1991).
Grip strength was assessed for both hands using
the Vigorimeter (Martin, Tuttlingen, Germany), an
instrument that has been used to measure grip
strength, and has fast and sustained responsiveness in
CIDP (Funfgeld, 1966; Hughes et al., 2008; Vanhoutte
et al., 2013). The pressure in the medium size bulb
is registered by a manometer via a rubber junction
tube and is expressed in kilopascals (kPa). The peak
(maximum) values of grip strength achieved during
each measurement were recorded as maximum grip
strength.
All selected centers were uniformly trained by an
expert clinimetrician (I. S. J. M.) aiming to standardize
the application of selected outcome measures for this
study. Each participating center was provided with a
research manual containing assessment instructions
for the selected outcome measures.
Efficacy and safety evaluation
The primary efficacy endpoint was the responder
rate by the adjusted INCAT score. The INCAT
score was measured at baseline and every 3 weeks
thereafter, until completion (Hughes et al., 2001).
The adjustment was introduced when comparing
two INCAT scores of the same patient to correct
for improvement in the upper limbs only: a change
from 1 to 0 or from 0 to 1 solely due to upper limbs
score was not considered to be clinically relevant.
Responders were defined as patients with a clinically
meaningful improvement (decrease of ≥1 point in
the adjusted INCAT score) between baseline and
completion (Week 25) or the last study visit in case of
premature discontinuation.
Secondary efficacy endpoints included time to first
clinically meaningful improvement either by adjusted
INCAT score (a decrease of ≥1 point) or MRC sum
score (an improvement of ≥3 points), and change
from baseline in adjusted INCAT score, maximum grip
strength of the dominant hand and MRC sum score. All
secondary endpoints were assessed at baseline and
every 3 weeks thereafter.
Safety endpoints were adverse event (AE) rate per
infusion, severity, and relatedness to study medication,
vital signs during infusion, and changes in laboratory
parameters compared to baseline. Information about
AEs and serious AEs (SAEs) was continuously
recorded by the investigator in the patient’s electronic
case report form starting from the time of written
informed consent until the completion visit or the last
study visit in case of premature discontinuation. All
AEs were followed up until resolution or until being
recognized as a permanent condition.
Vital signs including systolic and diastolic blood
pressure, heart rate, and body temperature were
measured repeatedly before, during and after the
infusion. Blood samples for measuring IgG levels were
taken during screening, before and after the infusion
on Week 1 (baseline), Week 7, Week 13 and Week 19,
and at the completion visit (Week 25).
In keeping with the ethical requirements of the ICH
GCP guidelines, this study used the single-arm study
design with a predefined success criterion based on a
recent placebo-controlled study of IVIG in patients with
CIDP in Europe (ICE study) (Hughes et al., 2008). The
PRIMA study was considered successful if the lower
limit of the 2-sided 95% Wilson-Score confidence
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interval (CI) of the responder rate by the adjusted
INCAT score was greater than 35%, based on the
responder rate in the placebo arm of the ICE study
(21%; 95% Wilson-Score CI: 12.3%–32.8%) (Hughes
et al., 2008).
Statistical methodology
The sample size was calculated based on the
predefined success criterion. Due to the lower number
of IVIG-naı¨ve patients in this study than in the ICE
study, a higher Privigen responder rate was assumed
(65% vs. 54% in the ICE study). With a sample size of
seven patients, the power to obtain a lower limit of the
2-sided 95% Wilson-Score CI of >35% was greater
than 90%. To address a potential misspecification
of the assumptions, a total of 30 patients were
planned to be enrolled to ensure at least 20 evaluable
patients.
Efficacy was determined in the intention-to-treat
(ITT) analysis that was based on the full analysis
set (FAS), defined as all patients who received at
least one infusion. The per-protocol (PP) analysis
was based on the valid cases set that included all
FAS patients without any major protocol deviation.
The primary efficacy endpoint was based on the
lower limit of the 2-sided 95% Wilson-Score CI for a
single proportion. For secondary efficacy endpoints,
the change from baseline to completion was ana-
lyzed using non-parametric Hodges–Lehmann point
estimates with the corresponding Tukey CI. The
time to first adjusted INCAT response and to first
MRC response was analyzed using the Kaplan–Meier
method.
The safety analysis was based on the safety
data set, which was identical to the FAS. Descrip-
tive statistics (mean, standard deviation [SD], median,
minimum, maximum, and 25%–75% quantile) were
calculated for all safety variables, including lab-
oratory parameters, vital signs, and serum IgG
levels.
Results
Patients
A total of 31 patients were screened at 13 sites
in Germany, Belgium, Poland, France, and Finland.
The study lasted from December 2010 to November
2011. Three patients did not meet the inclusion criteria,
including one patient who did not experience adjusted
INCAT score deterioration during the washout period.
Twenty-eight patients were enrolled (Table 1), of which
three patients were discontinued from the study (two
patients during the induction period due to SAEs of
hemolysis and one patient during the maintenance
Table 1. Demographic characteristics of patients.
Total number of patients 28
Gender, n (%)
Male 18 (64.3)
Female 10 (35.7)
Age (years), median (range) 58 (22–79)
Caucasians, n (%) 28 (100)
Body weight (kg), median (range) 83 (50–118)
BMI (kg/m2), median (range) 27.9 (18–36)
Height (cm), median (range) 172 (158–195)
Duration of CIDP, n (%)
≤1 year 9 (32.1)
>1 to ≤2years 4 (14.3)
>2 to ≤10years 12 (42.9)
>10years 3 (10.7)
Baseline disease characteristics
INCAT score, median (25%–75%
quantile)
3.5 (3.0–4.5)
Maximum grip strength (kPa),
mean (SD)
66.7 (37.24)
MRC sum score, median (25%–75%
quantile)
67.0 (61.5–72.0)
Serum IgG level (mg/dl), mean (SD) 1259.5 (377.47)
Demographic and baseline disease characteristics of all enrolled
patients are shown.
BMI, body mass index; CIDP, chronic inflammatory demyelinating
polyneuropathy; INCAT, Inflammatory Neuropathy Cause and
Treatment disability scale; MRC, Medical Research Council; n,
number of patients; SD, standard deviation.
Figure 1. Patient disposition. Of 31 screened patients, 28
were enrolled into the study and received the induction
Privigen® dose. A total of three patients discontinued during
the induction and maintenance phases, leaving 25 patients
who completed the study.
period due to ‘insufficient response to treatment’),
leaving 25 patients who completed the study (Fig. 1).
Thirteen patients (46.4%) had been previously
treated with IVIG, and 15 patients (53.6%) were IVIG-
naı¨ve. The most common (42.9%) time between the
CIDP diagnosis and enrollment into the study was
2–10 years (Table 1).
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Table 2. Number of responders by the adjusted INCAT
score at completion (ITT).
All
patients
IVIG-pretreated
patients
IVIG-naı¨ve
patients
Total number of
patients
28 13 15
Number of
responders, n
17 10 7
Responder rate (%) 60.7 76.9 46.7
Wilson-Score 95%
CI of the
responder rate (%)
42.4–76.4 49.7–91.8 24.8–69.9
The number and proportion of responders at completion are shown
for all patients and patient subgroups in the intention-to-treat (ITT)
analysis. Last observation carried forward was used to replace
missing values.
CI, confidence interval; INCAT, Inflammatory Neuropathy Cause and
Treatment disability scale; IVIG, intravenous immunoglobulin; n,
number of patients.
All patients received concomitant medication
during the study. Most common concomitant
medications were analgesics (60.7%), drugs for acid-
related disorders (39.3%), agents acting on the
renin-angiotensin system (39.3%), and non-steroid
anti-inflammatory drugs (NSAIDs) and antirheumatic
products (39.3%). Five patients (17.9%) received
corticosteroids for systemic use; two patients (7.1%)
received azathioprine for immunosuppression.
Study drug administration
During the induction period, 21 patients (75.0%)
received the Privigen induction dose of 2 g/kg bw over
2 days, five patients (17.9%) over 5 days, and two
patients (7.1%) over 3 days. The total dose of 2 g/kg
bw was split into equal daily amounts.
During the maintenance period, 24 patients
(85.7%) received each of the planned seven infusions
of 1 g/kg bw on a single day, and one patient received
them on 2 consecutive days. The mean of individual
patient median infusion rates was 5.89 mg/kg/min,
with a range of 1.48 to 8.36 mg/kg/min.
Efficacy
Primary efficacy endpoint
Seventeen (60.7%) of 28 patients in the ITT
analysis were responders by the adjusted INCAT score
at completion, with the 2-sided 95% Wilson-Score
CI of 42.41% to 76.43%, hence meeting the study
objectives (Table 2). In the PP analysis, 14 (63.6%)
of 22 patients were responders, showing an overall
responder rate similar to the ITT analysis (95% Wilson-
Score CI: 42.95%–80.27%).
Subgroups
IVIG-pretreated patients demonstrated a higher
responder rate (76.9%; 10 of 13 patients) than IVIG-
naı¨ve patients (46.7%; 7 of 15 patients). Characteristics
of the three IVIG-pretreated patients, who did not
respond, are shown in Table 3.
Secondary efficacy endpoints
Change from baseline in adjusted INCAT score:
The median (25%–75% quantile) adjusted INCAT
score improved from 3.5 (3.0–4.5) points at baseline
to 2.5 (1.0–3.0) points at completion, a reduction
Table 3. Characteristics of IVIG-pretreated non-responders.
Patient I Patient II Patient III
Previous IgG dosage (g) 90 160 84
Interval between the last IgG dose and the first Privigen® dose (days) 41 43 44
Privigen induction dose (g) 180 234 168
Privigen maintenance dose (g) 90 117 84
Screening
INCAT score 4 (2*) 2 4
MRC sum score 69 64 60
Maximum grip strength (kPa) 63 160 60
Baseline
INCAT score 3 3 6
MRC sum score 69 60 54
Maximum grip strength (kPa) 70 150 52
Completion
INCAT score 3 3 6
MRC sum score 74 75 57
Maximum grip strength (kPa) 110 140 62
Previous intravenous immunoglobulin (IVIG) treatment, Privigen dosage and efficacy measurements are shown for the three IVIG-pretreated
patients that did not respond to Privigen after the washout period. Please note that Patient I had no deterioration of the INCAT score during
the washout period and therefore should not have been included in the trial. Because he received Privigen treatment during the study, he was
included in the intention-to-treat (ITT) analysis, but not in the per-protocol (PP) analysis. INCAT score from a second, unscheduled screening
visit of Patient I, which led to inclusion of the patient into the study, is shown in brackets and marked with an asterisk (*).
INCAT, Inflammatory Neuropathy Cause and Treatment disability scale; MRC, Medical Research Council.
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Figure 2. Secondary efficacy outputs have improved from baseline to completion (ITT). The median INCAT score, the mean
maximum grip strength and the median MRC sum score are shown for all patients in the ITT analysis. Error bars represent
either SD (maximum grip strength) or 25% and 75% quantile (adjusted INCAT score and MRC sum score).
Figure 3. Mean adjusted Inflammatory Neuropathy Cause
and Treatment (INCAT) score over time by intra-
venous immunoglobulin (IVIG)-pretreatment (ITT). The mean
adjusted INCAT scores are shown for IVIG-pretreated
(dashed gray line) and IVIG-naı¨ve (solid black line) patients in
the ITT analysis. Last observation carried forward was used
to replace missing values. Error bars represent the standard
error of the mean.
indicating improvement (Fig. 2). The corresponding
Hodges–Lehmann estimator indicated a change in the
INCAT score of −1.3 points (95% CI: −2.0 to −0.5
points). The mean adjusted INCAT score improved
from baseline to completion in both IVIG-pretreated
and IVIG-naı¨ve patients (Fig. 3).
Time to first adjusted INCAT response: Until
completion, 18 of 28 patients responded at least
once, with the corresponding Kaplan–Meier estimate
of the response probability of 64.3% (95% CI:
46.5%–82.0%). Half of the responders (nine of 18
patients) showed a response after receiving the
induction dose, as assessed at Week 4, and seven
Figure 4. Response to treatment based on adjusted
Inflammatory Neuropathy Cause and Treatment (INCAT)
score by intravenous immunoglobulin (IVIG)-pretreatment
(ITT). Kaplan–Meier analysis of the proportion of responders
based on the adjusted INCAT score is shown for all patients
(blue), IVIG-naı¨ve (red), and IVIG-pretreated (green) patients
in the ITT analysis. The number of patients, who have
achieved a response at least once by the time point (n),
followed by the number of patients who have not yet
responded (N) is indicated as ‘n/N’ below the graph. Please
note that this analysis included 1 patient who had a response
at Week 19 and Week 22 but not at completion (Week 25),
resulting in 18 responders, 17 of which were responders at
completion (shown in brackets).
other patients showed a response by Week 10 (Fig.
4). One patient showed a response at Week 19
and Week 22 but not at completion (Week 25); this
patient was therefore considered a non-responder in
the primary endpoint analysis. IVIG-pretreated patients
demonstrated a shorter median time to first adjusted
INCAT response than IVIG-naı¨ve patients (3 weeks vs.
18 weeks; Fig. 4).
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Figure 5. Mean maximum grip strength and mean MRC sum
score over time (ITT). The mean maximum grip strength of
dominant hand and mean MRC sum score is shown for all
patients in the ITT analysis. Error bars represent the standard
error of the mean.
Maximum grip strength: The mean (SD) maximum
grip strength of the dominant hand increased from
66.7 (37.24) kPa at baseline to 80.9 (31.06) kPa
at completion (mean change of 14.0 kPa; 95% CI:
0.79–27.46 kPa; Fig. 2), with a plateau after Week 7
(Fig. 5). Analysis of the maximum grip strength in the
non-dominant hand showed similar results (data not
shown).
Muscle strength (MRC sum score): The median
(25%–75% quantile) MRC sum score increased from
67.0 (61.5–72.0) points at baseline to 75.5 (71.5–79.5)
points at completion (Fig. 2), with a plateau after Week
10 (Fig. 5). The corresponding Hodges–Lehmann
estimator indicated a change in the MRC score of
6.5 points (95% CI: 4.0–9.5 points).
Time to first MRC response: The median
(25%–75% quantile) time to first MRC response
was 6 weeks (3–9 weeks). On the basis of the MRC
sum score, 23 of 28 patients showed a response
at completion, with a Kaplan–Meier estimate of the
response probability of 84.8%. Thirteen of 15 IVIG-
naı¨ve patients and 10 of 13 IVIG-pretreated patients
were responders at completion by the MRC score,
with the corresponding probabilities of response of
86.7% and 81.5%, respectively.
Serum IgG levels
The mean post-infusion serum IgG levels were
almost two-fold greater than the pre-infusion IgG
levels (Table 4). The mean pre- and post-infusion
serum IgG levels slightly increased from baseline
(1259.5 mg/dl and 2859.2 mg/dl, respectively) to Week
7 (1750.0 mg/dl and 3228.8 mg/dl, respectively) and
remained stable until the end of the study. The mean
change in IgG levels from pre-infusion to post-infusion
was higher, although with greater variability, in patients
who had a response than in non-responders (Table 4).
Safety
Overall adverse events
Twenty-two patients (78.6%) experienced a total
of 108 AEs, with the overall AE rate of 0.417 AEs
per infusion. Ninety-five AEs (88.0%) were mild or
moderate in intensity and resolved by the end of
the reporting period. The most common AEs were
headache, pain in an extremity, hypertension, asthenia,
and leukopenia (Table 5).
Temporally associated and related adverse events
Nineteen patients (67.9%) experienced a total of
66 temporally associated AEs that occurred during
an infusion or within 72 h after the end of infusion
(0.255 temporally associated AEs per infusion). The
most common AEs were headache, hypertension, and
asthenia (Table 5).
Seventeen patients (60.7%) experienced 49
AEs considered at least possibly related to study
medication (0.189 related AEs per infusion) including
27 AEs in 13 patients (46.4%) during the induction
phase (0.370 related AEs per infusion) and 22 AEs in 11
patients (39.3%) during the maintenance phase (0.118
related AEs per infusion). The most common at least
Table 4. Pre- and post-infusion serum IgG levels (ITT).
All patients Responders Non-responders
Total number of patients 28 17 11
Serum IgG levels (mg/dl)
Pre-infusion, mean (SD) 1828.4 (547.7) 1881.3 (583.6) 1757.8 (490.9)
Post-infusion, mean (SD) 3363.5 (880.0) 3592.4 (939.7) 3081.8 (711.7)
Change from pre-infusion to post-infusion (mg/dl)
Mean (SD) 1574.0 (725.4) 1759.0 (758.8) 1342.7 (612.2)
Range −867 to 3,392 −867 to 3,392 84 to 2,685
The mean and standard deviation (SD) of the pre- and post-infusion serum IgG levels are shown for all patients in the intention-to-treat (ITT)
analysis, and for responders and non-responders at completion.
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Table 5. Most common temporally associated and possibly related AEs (ITT).
All AEs
Temporally associated
AEs (72hours) At least possibly related AEs
Number of
patients
(%)
AEs
(rate per
infusion)
Number of
patients
(%)
AEs
(rate per
infusion)
Number of
patients
(%)
AEs
(rate per
infusion)
Total number of patients or infusions 28 259 28 259 28 259
Headache 9 (32.1) 20 (0.077) 8 (28.6) 19 (0.073) 8 (28.6) 18 (0.069)
Pain in extremity 6 (21.4) 7 (0.027) 3 (10.7) 3 (0.012) n/a n/a
Hypertension 4 (14.3) 6 (0.023) 4 (14.3) 6 (0.023) 4 (14.3) 5 (0.019)
Asthenia 4 (14.3) 4 (0.015) 4 (14.3) 4 (0.015) 4 (14.3) 4 (0.015)
Leukopenia 4 (14.3) 4 (0.015) 0 0 2 (7.1) 2 (0.008)
Nausea 3 (10.7) 3 (0.012) 3 (10.7) 3 (0.012) 3 (10.7) 3 (0.012)
Arthralgia 2 (7.1) 3 (0.012) 1 (3.6) 1 (0.004) n/a n/a
Influenza-like illness 2 (7.1) 2 (0.008) 2 (7.1) 2 (0.008) 2 (7.1) 2 (0.008)
Hemolysis 2 (7.1) 2 (0.008) 2 (7.1) 2 (0.008) 2 (7.1) 2 (0.008)
Oropharyngeal pain 2 (7.1) 2 (0.008) 1 (3.6) 1 (0.004) n/a n/a
Contusion 2 (7.1) 2 (0.008) 0 0 n/a n/a
Rash 2 (7.1) 2 (0.008) 0 0 2 (7.1) 2 (0.008)
Numbers of patients and rates per infusion are shown for most common (≥3.5%) adverse events (AEs) for all patients in the intention-to-treat
(ITT) analysis. AEs that occurred during or within 72h after infusion were considered temporally associated. Relatedness of the AEs to study
medication was evaluated by the investigators.
n/a, data not available.
possibly related AEs were headache, hypertension,
and asthenia (Table 5).
Serious adverse events
Four patients (14.3%) experienced a total of four
SAEs, of which two cases of hemolysis during the
induction phase were assessed as related to study
medication (Table 6). Both patients were discontinued
from the study and recovered without sequelae. No
red blood cell transfusion was required for treatment
of hemolysis.
Two other SAEs (CIDP deterioration and worsen-
ing of chronic sigmoid diverticulitis) were considered
not related to Privigen. The SAE of CIDP deterioration
occurred 1 day prior to the first Privigen infusion and
was, therefore, clearly not related; the patient subse-
quently responded to study treatment already at Week
4. Both patients completed the study as per protocol
and recovered without sequelae.
No deaths occurred during the study.
Laboratory tests
Median values and ranges of hematology analytes
did not show any relevant changes over time.
Leukopenia was reported in four patients (14.3%)
with pre-existing leukopenia at screening, of which
two patients also had a medical history of leukopenia.
In the first patient, AEs of mild leukopenia were
reported at Week 19 (3,520/mm3; normal range:
4,800–10,800/mm3) and at Week 25 (3,740/mm3).
These AEs were considered possibly related to
Privigen. In the second patient, low leukocyte count
at Week 7 (1,730/mm3) was reported as an AE of
moderate leukopenia and was considered not related
to Privigen (considered a measurement artifact in
subsequent analysis). The third patient showed low
leukocyte count at Week 13 (2,330/mm3), which
was reported as an AE of mild leukopenia and was
considered unlikely related to Privigen. In the fourth
patient, AEs of mild leukopenia were reported at
Week 13 (2,320/mm3) and at Week 19 (3,100/mm3).
The values were reported as AEs of mild leukopenia
possibly related to Privigen.
An AE of moderate hyperbilirubinemia was
reported in one patient (3.6%) at Week 25
(2.62 mg/dl; normal range: 0.30–1.20 mg/dl). The AE
was considered not related to Privigen.
All laboratory test abnormalities resolved by the
final follow-up.
Discussion
Privigen, administered as a regimen of a 2 g/kg bw
induction dose and 1 g/kg bw maintenance doses every
3 weeks, resulted in an adjusted INCAT score-based
responder rate of 60.7%. The responder rate was
significantly higher than in the historical placebo group
(32.8%); hence, the study success criterion was met.
This result was supported by consistent improvements
in all secondary efficacy outcome measures (adjusted
INCAT score, maximum grip strength, and MRC
sum score) from baseline to completion. Nine of 17
responders showed a response after receiving the
induction dose, as assessed at Week 4. All but one
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Table 6. Hemolysis cases.
Patient A Patient B
Age (years) 56 46
Gender Female Male
ABO blood group AB A
CIDP diagnosis date June 2008 June 2009
Previous IVIG Privigen® Sandoglobulin®
Last previous dose of IVIG (g) 30 104
Total induction dose (g) 134 208
Induction period (days) 2 2
Induction date June 2011 March 2011
Concomitant medication Gabapentin, amlodipine,
hydrochlorothiazide, vitamin B
complex, enoxaparin
Methylprednisolone, bisoprolol,
azathioprine, cotrimoxazole,
escitalopram, zolpidem,
pantoprazole, trazodone, ibuprofen,
paracetamol
Hemolysis symptoms Headache, jaundice, Hb drop Fatigue, bilirubinuria, Hb drop
Time between induction and the onset of
symptoms (days)
2 2
Hemolysis intensity Mild Severe
Time until complete recovery after onset
of symptoms (days)
24.5 (11*) 33 (21*)
Hb level before event (g/dl) 11.8–14.7 15.9
Lowest measured Hb level (g/dl) 9.4 10.5
Time between the onset of symptoms and
the lowest measured Hb level (days)
4 4
Characteristics of two patients with hemolysis are shown, including demographics, Privigen dosage, previous and concomitant treatments
and hemolysis symptoms and duration. Times between the onset of symptoms and no active signs of hemolysis is shown in brackets and
marked with asterisks (*).
CIDP, chronic inflammatory demyelinating polyneuropathy; Hb, hemoglobin; IVIG, intravenous immunoglobulin.
of these patients demonstrated a clinically meaningful
improvement by Week 10. Thus, the PRIMA study
reported here demonstrated the efficacy of Privigen
treatment in patients with CIDP.
The results of the PRIMA study complement the
results of the previous studies supporting the efficacy
of IVIG in CIDP, including the ICE study (Hughes et al.,
2001; 2008). Owing to the longer duration than in the
ICE study, this study has demonstrated that patients
not responding after 6 weeks of IVIG treatment may
still show a response at a later time point, in contrast
to previously established views (Latov et al., 2010).
This result suggests that a longer treatment period
should be considered before declaring a patient a non-
responder to IVIG therapy.
Three of 13 IVIG-pretreated patients did not
respond to Privigen after the washout period and
re-introduction of the IVIG treatment. Two of these
patients had a relevant improvement in grip strength
and MRC sum score, but did not return to their
screening INCAT score. A probable explanation is
that the follow-up time was too short to allow for full
INCAT score-based recovery. In addition, one of these
patients did not deteriorate during the washout period,
indicating a possibility of CIDP becoming inactive
after the initial treatment, which is a known reason of
no response after re-introduction of the IgG therapy
(McCombe et al., 1987). The third non-responder
patient received a lower IVIG dose than previously
given (113 g every 3 weeks vs. 160 g every 3 weeks
before the washout period). This result indicates a
potential case of insufficient dosing. The proportion of
IVIG-naı¨ve responders in this study was slightly lower
than in the ICE study (46.7% vs. 51.3%); yet generally
in the same range (Hughes et al., 2008).
The PRIMA study showed that Privigen treatment
was well tolerated by patients with CIDP. Two patients
had SAEs of hemolysis that were considered at least
possibly related to Privigen, one of which had been on
regular Privigen before entering the study. Both SAEs
occurred within 2 days after the induction dose of Privi-
gen and resolved after discontinuation of the treatment
without further interventions (e.g., no blood trans-
fusion was necessary). Hemolysis is a known, rare
side effect of IVIG, with an increased risk in patients
receiving high doses of IVIG (such as those used in
immunomodulation for CIDP), with non-O blood group
and/or an underlying inflammatory state (Daw et al.,
2008; Padmore, 2012). All these risk factors (blood
groups A and AB, and a substantially increased IVIG
dose compared to previous treatment) were present in
both patients with hemolysis. Concomitant cotrimox-
azole treatment was considered a possible additional
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risk factor in one of the patients. A gallstone and con-
comitant medication (gabapentin and amlodipine) were
reported as an alternative causality in the other patient.
In a study in 57 patients with immune thrombocytope-
nia receiving Privigen, two cases of laboratory signs of
non-serious hemolytic reactions (anemia and positive
direct Coombs’ test) were reported that were transient
and did not require medical intervention (Robak et al.,
2009). In an ongoing post-marketing study of Privigen
in all registered indications, no cases of hemolysis have
been reported in 814 patients (Otremba et al., 2012).
These findings suggest that patients with risk factors
for hemolysis receiving IVIG must be monitored
carefully, as this AE can easily be overlooked.
Four episodes of mild leukopenia in two patients
with previous medical history of leukopenia were
considered at least possibly related to Privigen. IVIG-
related cytopenias are known to be often transient and
are usually not considered to be clinically significant
(Baxley and Akhtari, 2011).
One of the limitations of this study was the usage
of a historical control group. According to the ICH
GCP guidelines, using a placebo control in a second
study in the same patient population is not recom-
mended. Considering the availability of placebo data
in European patients with CIDP from the ICE study
(Hughes et al., 2008) and the relatively low prevalence
of CIDP (Joint Task Force of the EFNS and the PNS,
2010), the single-arm study design with a predefined
success criterion based on a historical control group
was chosen to show the efficacy of Privigen over
placebo. The active control design was not used,
because showing non-inferiority of Privigen to other
products was out of the scope of this study. Any other
study design (e.g., head-to-head comparison) would
have made it extremely difficult, if not impossible,
to recruit the required number of patients. Despite
these methodological limitations, the PRIMA study
provides sufficient evidence of efficacy and tolerability
of Privigen treatment in patients with CIDP.
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Appendix
List of investigators: Belgium: J. L. De Bleecker,
AZ St-Lucas, Gent (5 patients); W. Robberecht, UZ
Leuven, Leuven (3 patients). Finland: M. Saarela,
HUS Meilahti Hospital, Helsinki (3 patients). France:
J. Franques, Hoˆpital de la Timone, Neurologie et
Maladies Neuro-Musculaire, Marseille (2 patients);
J.-M. Le´ger, Groupe Hospitalier Pitie´-Salpeˆtrie`re Unite´
de Pathologie Neuro-Musculaire, Paris (1 patient);
R. Juntas Morales, CHRU Hoˆpital Gui de Chauliac,
Montpellier (1 patient). Germany: C. Sommer,
Universita¨tsklinikum Wu¨rzburg, Wu¨rzburg (4 patients);
A. Nguento, ASKLEPIOS Klinikum Uckermark GmbH,
Schwedt (2 patients); J. Schmidt, Universtita¨tsmedizin
Go¨ttingen, Georg-August-Universita¨t, Go¨ttingen (1
patient); Ch. Schrey, Facharzt fu¨r Neurologie, Berlin (1
patient). Poland: J. Kamienowski, Dolnos´la¸ski Szpital
Specjalistyczny, Wrocław (3 patients); Z. Stelmasiak,
Samodzielny Publiczny Szpital Kliniczny, Lublin (3
patients); G. Zwolin´ska, Centrum Neurologii Klinicznej,
Krako´w (2 patients).
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